Adapalene
Brand names: Differin, Epiduo (with benzoyl peroxide)
Adapalene is a topical retinoid used to treat mild-to-moderate acne vulgaris, often on the face and trunk.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It binds retinoic acid receptors to normalise follicular keratinocyte differentiation and reduce comedone formation, with additional anti-inflammatory activity.
Prescribing in practice
- Apply to clean dry skin and avoid the eyes, lips and mucous membranes, as it can cause local irritation, dryness and redness.
- It increases sensitivity to ultraviolet light, so excessive sun exposure and sunlamps should be avoided and sun protection used.
- Oral retinoids are teratogenic, and although systemic absorption from topical use is low, use in pregnancy should follow current prescribing references.
Monitoring
Monitor clinically for local tolerability and treatment response over several weeks.
Counselling the patient
- Apply a thin layer in the evening and expect a few weeks before improvement.
- Use sun protection as the skin becomes more sensitive to sunlight.
- Mild dryness or irritation often settles; reduce frequency if it is troublesome.
Evidence & guidelines
Topical retinoids such as adapalene are recommended as part of acne management in current UK guidance including NICE.
Reference: SmPC Differin / Epiduo; NICE NG198 (Acne vulgaris 2021); BAD Acne Guideline; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD